| 1 Kokubo Y. Epidemiology of transient ischemic attack[J]. Front Neurol Neurosci, 2014, 33:69-81. 2 Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack:a systematic review and meta-analysis[J]. Lancet Neurol, 2007, 6:1063-1072. 3 Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack[J]. Lancet, 2007, 369:283-292. 4 Amarenco P, Labreuche J, Lavallee PC. Patients with transient ischemic attack with ABCD2<4 can have similar 90-day stroke risk as patients with transient ischemic attack with ABCD2>/=4[J]. Stroke, 2012, 43:863-865. 5 Perry JJ, Sharma M, Sivilotti ML, et al. Prospective validation of the ABCD2 score for patients in the emergency department with transient ischemic attack[J]. CMAJ, 2011, 183:1137-1145. 6 Merwick A, Albers GW, Amarenco P, et al. Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack:a multicentre observational study[J]. Lancet Neurol, 2010, 9:1060-1069. 7 Neidert S, Katan M, Schuetz P, et al. Anterior pituitary axis hormones and outcome in acute ischaemic stroke[J]. J Intern Med, 2011, 269:420-432. 8 Katan M, Fluri F, Morgenthaler NG, et al. Copeptin:a novel, independent prognostic marker in patients with ischemic stroke[J]. Ann Neurol, 2009, 66:799-808. 9 Katan M, Nigro N, Fluri F, et al. Stress hormones predict cerebrovascular re-events after transient ischemic attacks[J]. Neurology, 2011, 76:563-566.10 De Marchis GM, Weck A, Audebert H, et al. Copeptin for the prediction of recurrent cerebrovascular events after transient ischemic attack:results from the CoRisk study[J]. Stroke, 2014, 45:2918-2923.11 Tobin MK, Bonds JA, Minshall RD, et al. Neurogenesis and inflammation after ischemic stroke:what is known and where we go from here[J]. J Cereb Blood Flow Metab, 2014, 34:1573-1584.12 Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality:an individual participant meta-analysis[J]. Lancet, 2010, 375:132-140.13 Purroy F, Montaner J, Molina CA, et al. C-reactive protein predicts further ischemic events in transient ischemic attack patients[J]. Acta Neurol Scand, 2007, 115:60-66.14 Corso G, Bottacchi E, Brusa A, et al. Blood C-reactive protein concentration with ABCD(2) is a better prognostic tool than ABCD(2) alone[J]. Cerebrovasc Dis, 2011, 32:97-105.15 Cucchiara B L, Messe SR, Sansing L, et al. Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA[J]. Stroke, 2009, 40:2332-2336.16 Cai A, Zheng D, Qiu R, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA[2]):a novel and promising biomarker for cardiovascular risks assessment[J]. Dis Markers, 2013, 34:323-331.17 Vittos O, Toana B, Vittos A, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2):a review of its role and significance as a cardiovascular biomarker[J]. Biomarkers, 2012, 17:289-302.18 Massot A, Pelegri D, Penalba A, et al. Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease[J]. Atherosclerosis, 2011, 218:181-187.19 Delgado P, Chacon P, Penalba A, et al. Lipoprotein-associated phospholipase A(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in TIA patients[J]. Cerebrovasc Dis, 2012, 33:150-158.20 Whiteley W, Jackson C, Lewis S, et al. Inflammatory markers and poor outcome after stroke:a prospective cohort study and systematic review of interleukin-6[J]. PLoS Med, 2009, 6:e1000145.21 Simundic AM, Basic V, Topic E, et al. Soluble adhesion molecules in acute ischemic stroke[J]. Clin Invest Med, 2004, 27:86-92.22 Selvarajah JR, Smith CJ, Hulme S, et al. Does inflammation predispose to recurrent vascular events after recent transient ischaemic attack and minor stroke? The North West of England transient ischaemic attack and minor stroke (NORTHSTAR) study[J]. Int J Stroke, 2011, 6:187-194.23 Whiteley W, Wardlaw J, Dennis M, et al. The use of blood biomarkers to predict poor outcome after acute transient ischemic attack or ischemic stroke[J]. Stroke, 2012, 43:86-91.24 Mustonen P, Lehtonen KV, Javela K, et al. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events:a nationwide prospective study[J]. Lupus, 2014, 23:1468-1476.25 Mullen MT, Messe SR, Kasner SE, et al. Anti-phosphatidylserine-prothrombin antibodies are associated with outcome in a TIA cohort[J]. Front Neurol, 2012, 3:137.26 De Meyer SF, Stoll G, Wagner DD, et al. von Willebrand factor:an emerging target in stroke therapy[J]. Stroke, 2012, 43:599-606.27 Di Castelnuovo A, Agnoli C, De Curtis A, et al. Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke. Findings from the EPICOR Study[J]. Thromb Haemost, 2014, 112:941-946.28 Segal HC, Burgess AI, Poole DL, et al. Population-based study of blood biomarkers in prediction of subacute recurrent stroke[J]. Stroke, 2014, 45:2912-2917.29 Greisenegger S, Segal HC, Burgess AI, et al. Biomarkers and mortality after transient ischemic attack and minor ischemic stroke:population-based study[J]. Stroke, 2015, 46:659-666.30 Mauri-Capdevila G, Jove M, Suarez-Luis I, et al. Metabolomics in ischaemic stroke, new diagnostic and prognostic biomarkers[J]. Rev Neurol, 2013, 57:29-36.31 Jiang Z, Sun J, Liang Q, et al. A metabonomic approach applied to predict patients with cerebral infarction[J]. Talanta, 2011, 84:298-304.32 Zhan X, Jickling G C, Tian Y, et al. Transient ischemic attacks characterized by RNA profiles in blood[J]. Neurology, 2011, 77:1718-1724.33 Jove M, Mauri-Capdevila G, Suarez I, et al. Metabolomics predicts stroke recurrence after transient ischemic attack[J]. Neurology, 2015, 84:36-45. |
